Pharmacological action Orlistat 120 mg:
Orlistat Specific inhibitor of gastrointestinal lipases. Forms a covalent bond with the active serine site of gastric and pancreatic lipases in the lumen of the stomach and small intestine. Inactivated the enzyme loses its ability to break down fats, food, coming in the form of triglycerides. Unsplit TG is not absorbed, and resulting reduction of calorie intake in the body leads to a decrease in body weight. Increases the concentration of fat in the feces 24-48 h after administration. Provides effective control of body weight, decrease body fat depot.
Uses Orlistat 120 mg:
Obesity (in the case, unless the diet have led to a weight loss of at least 2.5 kg over 4 weeks).
Contraindications Orlistat 120 mg:
Hypersensitivity, malabsorption syndrome, holestaz.C caution. Pregnancy, lactation.
Side effects Orlistat 120 mg:
Bloating, urgency of defecation, oily stools, increased defecation, fecal incontinence, and allergic reactions.
Dosage and administration:
Inside, 120 mg 3 times daily with each meal or not later than 1 hour after meals (if the food contains no fat, then you can skip the reception.)
Cautions Orlistat 120 mg:
During the period of treatment must be balanced, low-calorie diet containing no more than 30% kalorazh as fat and rich in fruits and vegetables (perhaps a multivitamin supplementation to compensate for the decrease in absorption of fat-soluble vitamins). Daily consumption of fats, carbohydrates and protein should be distributed in three main reception. If you take on the background of a diet rich in fat (67 g / d), the likelihood of side effects from the gastrointestinal tract is increased. Increasing the dose above the recommended does not lead to increased therapeutic effect. Treatment should not last more than 2 years. Not intended for use in pediatric practice.
Interaction Orlistat 120 mg:
And increases the bioavailability of lipid-lowering effect of pravastatin, increasing its plasma concentration by 30%. Reduces the absorption of fat soluble vitamins. Weight loss can improve the metabolism in diabetic patients, resulting need to reduce the dose of oral hypoglycemic drugs. Clinically significant interactions with digoxin, phenytoin, oral contraceptives, nifedipine, glibenclamide, furosemide, captopril, atenolol, and ethanol were not observed.
